Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21940659 | 0.87 | PTPN11 (0.47) | PTPN11KCNH2 | |
| SCHEMBL23046087 | 0.87 | PTPN11 (0.47) | PTPN11KCNH2 | |
| SCHEMBL24388823 | 0.87 | PTPN11 (0.47) | PTPN11KCNH2 | |
| Hydrochloric Acid SCHEMBL29804135 | 0.84 | HTR2A (0.42) | PTPN11KCNH2 | |
| SCHEMBL21397503 | 0.83 | PTPN11 (0.41) | PTPN11KCNH2 | |
| SCHEMBL22523741 | 0.81 | KCNH2 (0.47) | PTPN11KCNH2 | |
| SCHEMBL22520446 | 0.81 | CYP2D6 (0.47) | PTPN11KCNH2 | |
| SCHEMBL23508887 | 0.81 | KCNH2 (0.47) | PTPN11KCNH2 | |
| SCHEMBL21887295 | 0.81 | KCNH2 (0.47) | PTPN11KCNH2 | |
| SCHEMBL22520440 | 0.81 | CYP2D6 (0.47) | PTPN11KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12233062-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2025-02-25 | — | — | US | disclosed |
| US-20240285617-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-08-29 | — | — | US | disclosed |
| US-20240245681-A1 | HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBO PHARMACEUTICATS CO LTD (CN) | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245681-A1 | HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | PTPN1, PTPN5, PTPN2 | PTPN11 11/4885KCNH2 4262/4885 |
| US-20240285617-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | PTPN1, PTPN5, PTPN2 | PTPN11 9/4885KCNH2 4301/4885 |
| US-12233062-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | PTPN1, PTPN5, PTPN2 | PTPN11 11/4885KCNH2 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.